DNDi Offers Model for Pandemic Accord Negotiators on How Governments Can Leverage Drug R&D Investment 13/04/2023 Kerry Cullinan When governments invest in drug research and development (R&D) with pharmaceutical companies, they should ensure upfront that these drugs are affordable and widely available – and a global pandemic accord needs to provide high-level guidance on how to do this. This is the view of the Drugs for Neglected Diseases initiative (DNDi), a non-profit group […] Continue reading -> A ‘Simple Career’: The Untold Story of Bernard Pécoul and a Paradigm Shift in Global Health 10/10/2022 Stefan Anderson Under the leadership of Dr Bernard Pécoul, the Drugs for Neglected Diseases Initiative became one of the flagship programmes for research and development into diseases affecting the world’s most forgotten people. He has contributed to the betterment of the lives of millions, yet few outside global health circles know his name. This is his story. […] Continue reading -> Breaking: DNDi Founder Bernard Pécoul Steps Down After 19 Years 05/09/2022 Stefan Anderson The Drugs for Neglected Diseases initiative (DNDi), one of the most important nonprofit drug developers in the world, has appointed a new leader to fill the shoes of its outgoing founder. Dr Luis Pizarro, a Chilean-French doctor and global health expert, will serve as DNDi’s new executive director, succeeding DNDi founder Dr Bernard Pécoul, who […] Continue reading -> More Reliable Funding for WHO, Slow Progress on Pandemic Reform & Ukraine Controversy – What to Watch at the World Health Assembly 20/05/2022 Elaine Ruth Fletcher More stable funding for WHO, but only incremental progress on reforms in global pandemic response are expected out of the upcoming World Health Assembly, where member states also will debate and discuss over two dozen other critical health issues that don’t always make the headlines. The 75th World Health Assembly, WHO’s annual meeting of member […] Continue reading -> Data-Sharing in the Time of COVID – Could Researchers Agree to Use a Common Clinical Trial ‘Repository’? 15/04/2022 Elaine Ruth Fletcher Nathalie Strub-Wourgaft, a senior scientist at the Drugs for Neglected Disease Initiative (DNDi) has a vision that could be critical to halting the next pandemic – but is esoteric, difficult to organize and even more challenging to build the trust and buy-in needed to make it really work. The vision is of a common clinical-trial […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> The Moonshot: Crowdsourcing to Develop the First Open-Source, Generic COVID-19 Antiviral Pill 24/12/2021 Annette von Delft, Charles Mowbray & Borna Nyaoke A global grassroots movement of scientists based on crowdsourcing ideas, expertise, and goodwill has already generated – and freely released – more than half of the known structural information on the main protease of SARS-CoV-2. Based on this, they are now on a quest for an open-source drug that can block the virus from replicating. […] Continue reading -> COVID-19 Therapeutics Must be Shared to Avoid Replicating Vaccine Inequality, Warns DNDi 06/08/2021 Kerry Cullinan Much more global attention needs to be paid to developing early therapeutics to protect patients with COVID-19 from “hospitalisation, intensive care, or worse”, according to a report from Drugs for Neglected Diseases initiative (DNDi) released on Thursday. In addition, the few innovative treatments that exist are mostly available in high-income countries, and DNDi warns that […] Continue reading -> The ‘Silent Pandemic’ of Antimicrobial Resistance – Lessons Learned From COVID-19 30/04/2021 Raisa Santos In the midst of the COVID-19 pandemic, a “silent pandemic” of drug resistance to mutated bacteria, viruses and parasites is gaining ground and requires major government investments in antibiotic research and development (R&D), a group of experts has warned. “People are dying across the world from drug-resistant infections. This is a problem of today, and […] Continue reading -> DNDi Strategy For The Decade: Delivering And Developing Treatments For Neglected Tropical Diseases 01/04/2021 Raisa Santos Global health experts expressed their frustration with the lack of research and attention towards neglected tropical diseases (NTDs) and vulnerable populations, calling for health systems to address NTDs in a more sustainable and holistic way. Speaking at the launch of a new strategic plan for the Geneva-based Drugs for Neglected Diseases initiative (DNDi) on Tuesday, […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
A ‘Simple Career’: The Untold Story of Bernard Pécoul and a Paradigm Shift in Global Health 10/10/2022 Stefan Anderson Under the leadership of Dr Bernard Pécoul, the Drugs for Neglected Diseases Initiative became one of the flagship programmes for research and development into diseases affecting the world’s most forgotten people. He has contributed to the betterment of the lives of millions, yet few outside global health circles know his name. This is his story. […] Continue reading -> Breaking: DNDi Founder Bernard Pécoul Steps Down After 19 Years 05/09/2022 Stefan Anderson The Drugs for Neglected Diseases initiative (DNDi), one of the most important nonprofit drug developers in the world, has appointed a new leader to fill the shoes of its outgoing founder. Dr Luis Pizarro, a Chilean-French doctor and global health expert, will serve as DNDi’s new executive director, succeeding DNDi founder Dr Bernard Pécoul, who […] Continue reading -> More Reliable Funding for WHO, Slow Progress on Pandemic Reform & Ukraine Controversy – What to Watch at the World Health Assembly 20/05/2022 Elaine Ruth Fletcher More stable funding for WHO, but only incremental progress on reforms in global pandemic response are expected out of the upcoming World Health Assembly, where member states also will debate and discuss over two dozen other critical health issues that don’t always make the headlines. The 75th World Health Assembly, WHO’s annual meeting of member […] Continue reading -> Data-Sharing in the Time of COVID – Could Researchers Agree to Use a Common Clinical Trial ‘Repository’? 15/04/2022 Elaine Ruth Fletcher Nathalie Strub-Wourgaft, a senior scientist at the Drugs for Neglected Disease Initiative (DNDi) has a vision that could be critical to halting the next pandemic – but is esoteric, difficult to organize and even more challenging to build the trust and buy-in needed to make it really work. The vision is of a common clinical-trial […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> The Moonshot: Crowdsourcing to Develop the First Open-Source, Generic COVID-19 Antiviral Pill 24/12/2021 Annette von Delft, Charles Mowbray & Borna Nyaoke A global grassroots movement of scientists based on crowdsourcing ideas, expertise, and goodwill has already generated – and freely released – more than half of the known structural information on the main protease of SARS-CoV-2. Based on this, they are now on a quest for an open-source drug that can block the virus from replicating. […] Continue reading -> COVID-19 Therapeutics Must be Shared to Avoid Replicating Vaccine Inequality, Warns DNDi 06/08/2021 Kerry Cullinan Much more global attention needs to be paid to developing early therapeutics to protect patients with COVID-19 from “hospitalisation, intensive care, or worse”, according to a report from Drugs for Neglected Diseases initiative (DNDi) released on Thursday. In addition, the few innovative treatments that exist are mostly available in high-income countries, and DNDi warns that […] Continue reading -> The ‘Silent Pandemic’ of Antimicrobial Resistance – Lessons Learned From COVID-19 30/04/2021 Raisa Santos In the midst of the COVID-19 pandemic, a “silent pandemic” of drug resistance to mutated bacteria, viruses and parasites is gaining ground and requires major government investments in antibiotic research and development (R&D), a group of experts has warned. “People are dying across the world from drug-resistant infections. This is a problem of today, and […] Continue reading -> DNDi Strategy For The Decade: Delivering And Developing Treatments For Neglected Tropical Diseases 01/04/2021 Raisa Santos Global health experts expressed their frustration with the lack of research and attention towards neglected tropical diseases (NTDs) and vulnerable populations, calling for health systems to address NTDs in a more sustainable and holistic way. Speaking at the launch of a new strategic plan for the Geneva-based Drugs for Neglected Diseases initiative (DNDi) on Tuesday, […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Breaking: DNDi Founder Bernard Pécoul Steps Down After 19 Years 05/09/2022 Stefan Anderson The Drugs for Neglected Diseases initiative (DNDi), one of the most important nonprofit drug developers in the world, has appointed a new leader to fill the shoes of its outgoing founder. Dr Luis Pizarro, a Chilean-French doctor and global health expert, will serve as DNDi’s new executive director, succeeding DNDi founder Dr Bernard Pécoul, who […] Continue reading -> More Reliable Funding for WHO, Slow Progress on Pandemic Reform & Ukraine Controversy – What to Watch at the World Health Assembly 20/05/2022 Elaine Ruth Fletcher More stable funding for WHO, but only incremental progress on reforms in global pandemic response are expected out of the upcoming World Health Assembly, where member states also will debate and discuss over two dozen other critical health issues that don’t always make the headlines. The 75th World Health Assembly, WHO’s annual meeting of member […] Continue reading -> Data-Sharing in the Time of COVID – Could Researchers Agree to Use a Common Clinical Trial ‘Repository’? 15/04/2022 Elaine Ruth Fletcher Nathalie Strub-Wourgaft, a senior scientist at the Drugs for Neglected Disease Initiative (DNDi) has a vision that could be critical to halting the next pandemic – but is esoteric, difficult to organize and even more challenging to build the trust and buy-in needed to make it really work. The vision is of a common clinical-trial […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> The Moonshot: Crowdsourcing to Develop the First Open-Source, Generic COVID-19 Antiviral Pill 24/12/2021 Annette von Delft, Charles Mowbray & Borna Nyaoke A global grassroots movement of scientists based on crowdsourcing ideas, expertise, and goodwill has already generated – and freely released – more than half of the known structural information on the main protease of SARS-CoV-2. Based on this, they are now on a quest for an open-source drug that can block the virus from replicating. […] Continue reading -> COVID-19 Therapeutics Must be Shared to Avoid Replicating Vaccine Inequality, Warns DNDi 06/08/2021 Kerry Cullinan Much more global attention needs to be paid to developing early therapeutics to protect patients with COVID-19 from “hospitalisation, intensive care, or worse”, according to a report from Drugs for Neglected Diseases initiative (DNDi) released on Thursday. In addition, the few innovative treatments that exist are mostly available in high-income countries, and DNDi warns that […] Continue reading -> The ‘Silent Pandemic’ of Antimicrobial Resistance – Lessons Learned From COVID-19 30/04/2021 Raisa Santos In the midst of the COVID-19 pandemic, a “silent pandemic” of drug resistance to mutated bacteria, viruses and parasites is gaining ground and requires major government investments in antibiotic research and development (R&D), a group of experts has warned. “People are dying across the world from drug-resistant infections. This is a problem of today, and […] Continue reading -> DNDi Strategy For The Decade: Delivering And Developing Treatments For Neglected Tropical Diseases 01/04/2021 Raisa Santos Global health experts expressed their frustration with the lack of research and attention towards neglected tropical diseases (NTDs) and vulnerable populations, calling for health systems to address NTDs in a more sustainable and holistic way. Speaking at the launch of a new strategic plan for the Geneva-based Drugs for Neglected Diseases initiative (DNDi) on Tuesday, […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
More Reliable Funding for WHO, Slow Progress on Pandemic Reform & Ukraine Controversy – What to Watch at the World Health Assembly 20/05/2022 Elaine Ruth Fletcher More stable funding for WHO, but only incremental progress on reforms in global pandemic response are expected out of the upcoming World Health Assembly, where member states also will debate and discuss over two dozen other critical health issues that don’t always make the headlines. The 75th World Health Assembly, WHO’s annual meeting of member […] Continue reading -> Data-Sharing in the Time of COVID – Could Researchers Agree to Use a Common Clinical Trial ‘Repository’? 15/04/2022 Elaine Ruth Fletcher Nathalie Strub-Wourgaft, a senior scientist at the Drugs for Neglected Disease Initiative (DNDi) has a vision that could be critical to halting the next pandemic – but is esoteric, difficult to organize and even more challenging to build the trust and buy-in needed to make it really work. The vision is of a common clinical-trial […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> The Moonshot: Crowdsourcing to Develop the First Open-Source, Generic COVID-19 Antiviral Pill 24/12/2021 Annette von Delft, Charles Mowbray & Borna Nyaoke A global grassroots movement of scientists based on crowdsourcing ideas, expertise, and goodwill has already generated – and freely released – more than half of the known structural information on the main protease of SARS-CoV-2. Based on this, they are now on a quest for an open-source drug that can block the virus from replicating. […] Continue reading -> COVID-19 Therapeutics Must be Shared to Avoid Replicating Vaccine Inequality, Warns DNDi 06/08/2021 Kerry Cullinan Much more global attention needs to be paid to developing early therapeutics to protect patients with COVID-19 from “hospitalisation, intensive care, or worse”, according to a report from Drugs for Neglected Diseases initiative (DNDi) released on Thursday. In addition, the few innovative treatments that exist are mostly available in high-income countries, and DNDi warns that […] Continue reading -> The ‘Silent Pandemic’ of Antimicrobial Resistance – Lessons Learned From COVID-19 30/04/2021 Raisa Santos In the midst of the COVID-19 pandemic, a “silent pandemic” of drug resistance to mutated bacteria, viruses and parasites is gaining ground and requires major government investments in antibiotic research and development (R&D), a group of experts has warned. “People are dying across the world from drug-resistant infections. This is a problem of today, and […] Continue reading -> DNDi Strategy For The Decade: Delivering And Developing Treatments For Neglected Tropical Diseases 01/04/2021 Raisa Santos Global health experts expressed their frustration with the lack of research and attention towards neglected tropical diseases (NTDs) and vulnerable populations, calling for health systems to address NTDs in a more sustainable and holistic way. Speaking at the launch of a new strategic plan for the Geneva-based Drugs for Neglected Diseases initiative (DNDi) on Tuesday, […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Data-Sharing in the Time of COVID – Could Researchers Agree to Use a Common Clinical Trial ‘Repository’? 15/04/2022 Elaine Ruth Fletcher Nathalie Strub-Wourgaft, a senior scientist at the Drugs for Neglected Disease Initiative (DNDi) has a vision that could be critical to halting the next pandemic – but is esoteric, difficult to organize and even more challenging to build the trust and buy-in needed to make it really work. The vision is of a common clinical-trial […] Continue reading -> Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> The Moonshot: Crowdsourcing to Develop the First Open-Source, Generic COVID-19 Antiviral Pill 24/12/2021 Annette von Delft, Charles Mowbray & Borna Nyaoke A global grassroots movement of scientists based on crowdsourcing ideas, expertise, and goodwill has already generated – and freely released – more than half of the known structural information on the main protease of SARS-CoV-2. Based on this, they are now on a quest for an open-source drug that can block the virus from replicating. […] Continue reading -> COVID-19 Therapeutics Must be Shared to Avoid Replicating Vaccine Inequality, Warns DNDi 06/08/2021 Kerry Cullinan Much more global attention needs to be paid to developing early therapeutics to protect patients with COVID-19 from “hospitalisation, intensive care, or worse”, according to a report from Drugs for Neglected Diseases initiative (DNDi) released on Thursday. In addition, the few innovative treatments that exist are mostly available in high-income countries, and DNDi warns that […] Continue reading -> The ‘Silent Pandemic’ of Antimicrobial Resistance – Lessons Learned From COVID-19 30/04/2021 Raisa Santos In the midst of the COVID-19 pandemic, a “silent pandemic” of drug resistance to mutated bacteria, viruses and parasites is gaining ground and requires major government investments in antibiotic research and development (R&D), a group of experts has warned. “People are dying across the world from drug-resistant infections. This is a problem of today, and […] Continue reading -> DNDi Strategy For The Decade: Delivering And Developing Treatments For Neglected Tropical Diseases 01/04/2021 Raisa Santos Global health experts expressed their frustration with the lack of research and attention towards neglected tropical diseases (NTDs) and vulnerable populations, calling for health systems to address NTDs in a more sustainable and holistic way. Speaking at the launch of a new strategic plan for the Geneva-based Drugs for Neglected Diseases initiative (DNDi) on Tuesday, […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
Pfizer Refuses Cooperation with DNDi on Study of Paxlovid Treatment Adapted to Low Income Countries 08/04/2022 Elaine Ruth Fletcher & Kerry Cullinan Pfizer has so far refused an invitation from the Geneva-based Drugs for Neglected Diseases Initiative (DNDi) to cooperate on a study exploring whether the treatment window of its successful antiviral drug, Paxlovid, could be extended from 5-7 days using another drug compound in addition, Dr Nathalie Strub-Wourgaft, Director of DNDi’s COVID-19 Response, told Health Policy […] Continue reading -> The Moonshot: Crowdsourcing to Develop the First Open-Source, Generic COVID-19 Antiviral Pill 24/12/2021 Annette von Delft, Charles Mowbray & Borna Nyaoke A global grassroots movement of scientists based on crowdsourcing ideas, expertise, and goodwill has already generated – and freely released – more than half of the known structural information on the main protease of SARS-CoV-2. Based on this, they are now on a quest for an open-source drug that can block the virus from replicating. […] Continue reading -> COVID-19 Therapeutics Must be Shared to Avoid Replicating Vaccine Inequality, Warns DNDi 06/08/2021 Kerry Cullinan Much more global attention needs to be paid to developing early therapeutics to protect patients with COVID-19 from “hospitalisation, intensive care, or worse”, according to a report from Drugs for Neglected Diseases initiative (DNDi) released on Thursday. In addition, the few innovative treatments that exist are mostly available in high-income countries, and DNDi warns that […] Continue reading -> The ‘Silent Pandemic’ of Antimicrobial Resistance – Lessons Learned From COVID-19 30/04/2021 Raisa Santos In the midst of the COVID-19 pandemic, a “silent pandemic” of drug resistance to mutated bacteria, viruses and parasites is gaining ground and requires major government investments in antibiotic research and development (R&D), a group of experts has warned. “People are dying across the world from drug-resistant infections. This is a problem of today, and […] Continue reading -> DNDi Strategy For The Decade: Delivering And Developing Treatments For Neglected Tropical Diseases 01/04/2021 Raisa Santos Global health experts expressed their frustration with the lack of research and attention towards neglected tropical diseases (NTDs) and vulnerable populations, calling for health systems to address NTDs in a more sustainable and holistic way. Speaking at the launch of a new strategic plan for the Geneva-based Drugs for Neglected Diseases initiative (DNDi) on Tuesday, […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
The Moonshot: Crowdsourcing to Develop the First Open-Source, Generic COVID-19 Antiviral Pill 24/12/2021 Annette von Delft, Charles Mowbray & Borna Nyaoke A global grassroots movement of scientists based on crowdsourcing ideas, expertise, and goodwill has already generated – and freely released – more than half of the known structural information on the main protease of SARS-CoV-2. Based on this, they are now on a quest for an open-source drug that can block the virus from replicating. […] Continue reading -> COVID-19 Therapeutics Must be Shared to Avoid Replicating Vaccine Inequality, Warns DNDi 06/08/2021 Kerry Cullinan Much more global attention needs to be paid to developing early therapeutics to protect patients with COVID-19 from “hospitalisation, intensive care, or worse”, according to a report from Drugs for Neglected Diseases initiative (DNDi) released on Thursday. In addition, the few innovative treatments that exist are mostly available in high-income countries, and DNDi warns that […] Continue reading -> The ‘Silent Pandemic’ of Antimicrobial Resistance – Lessons Learned From COVID-19 30/04/2021 Raisa Santos In the midst of the COVID-19 pandemic, a “silent pandemic” of drug resistance to mutated bacteria, viruses and parasites is gaining ground and requires major government investments in antibiotic research and development (R&D), a group of experts has warned. “People are dying across the world from drug-resistant infections. This is a problem of today, and […] Continue reading -> DNDi Strategy For The Decade: Delivering And Developing Treatments For Neglected Tropical Diseases 01/04/2021 Raisa Santos Global health experts expressed their frustration with the lack of research and attention towards neglected tropical diseases (NTDs) and vulnerable populations, calling for health systems to address NTDs in a more sustainable and holistic way. Speaking at the launch of a new strategic plan for the Geneva-based Drugs for Neglected Diseases initiative (DNDi) on Tuesday, […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
COVID-19 Therapeutics Must be Shared to Avoid Replicating Vaccine Inequality, Warns DNDi 06/08/2021 Kerry Cullinan Much more global attention needs to be paid to developing early therapeutics to protect patients with COVID-19 from “hospitalisation, intensive care, or worse”, according to a report from Drugs for Neglected Diseases initiative (DNDi) released on Thursday. In addition, the few innovative treatments that exist are mostly available in high-income countries, and DNDi warns that […] Continue reading -> The ‘Silent Pandemic’ of Antimicrobial Resistance – Lessons Learned From COVID-19 30/04/2021 Raisa Santos In the midst of the COVID-19 pandemic, a “silent pandemic” of drug resistance to mutated bacteria, viruses and parasites is gaining ground and requires major government investments in antibiotic research and development (R&D), a group of experts has warned. “People are dying across the world from drug-resistant infections. This is a problem of today, and […] Continue reading -> DNDi Strategy For The Decade: Delivering And Developing Treatments For Neglected Tropical Diseases 01/04/2021 Raisa Santos Global health experts expressed their frustration with the lack of research and attention towards neglected tropical diseases (NTDs) and vulnerable populations, calling for health systems to address NTDs in a more sustainable and holistic way. Speaking at the launch of a new strategic plan for the Geneva-based Drugs for Neglected Diseases initiative (DNDi) on Tuesday, […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy Loading Comments... You must be logged in to post a comment.
The ‘Silent Pandemic’ of Antimicrobial Resistance – Lessons Learned From COVID-19 30/04/2021 Raisa Santos In the midst of the COVID-19 pandemic, a “silent pandemic” of drug resistance to mutated bacteria, viruses and parasites is gaining ground and requires major government investments in antibiotic research and development (R&D), a group of experts has warned. “People are dying across the world from drug-resistant infections. This is a problem of today, and […] Continue reading -> DNDi Strategy For The Decade: Delivering And Developing Treatments For Neglected Tropical Diseases 01/04/2021 Raisa Santos Global health experts expressed their frustration with the lack of research and attention towards neglected tropical diseases (NTDs) and vulnerable populations, calling for health systems to address NTDs in a more sustainable and holistic way. Speaking at the launch of a new strategic plan for the Geneva-based Drugs for Neglected Diseases initiative (DNDi) on Tuesday, […] Continue reading -> Posts navigation Older posts This site uses cookies to help give you the best experience on our website. Cookies enable us to collect information that helps us personalise your experience and improve the functionality and performance of our site. By continuing to read our website, we assume you agree to this, otherwise you can adjust your browser settings. Please read our cookie and Privacy Policy. Our Cookies and Privacy Policy
DNDi Strategy For The Decade: Delivering And Developing Treatments For Neglected Tropical Diseases 01/04/2021 Raisa Santos Global health experts expressed their frustration with the lack of research and attention towards neglected tropical diseases (NTDs) and vulnerable populations, calling for health systems to address NTDs in a more sustainable and holistic way. Speaking at the launch of a new strategic plan for the Geneva-based Drugs for Neglected Diseases initiative (DNDi) on Tuesday, […] Continue reading -> Posts navigation Older posts